Literature DB >> 21389094

Previous exposure to delta9-tetrahydrocannibinol enhances locomotor responding to but not self-administration of amphetamine.

James J Cortright1, Daniel S Lorrain, Jeff A Beeler, Wei-Jen Tang, Paul Vezina.   

Abstract

Previous exposure to amphetamine leads to enhanced locomotor and nucleus accumbens (NAcc) dopamine (DA) responding to the drug as well as enhanced amphetamine self-administration. Here, we investigated the effects of exposure to Δ(9)-tetrahydrocannibinol (Δ(9)-THC) on behavioral and biochemical responding to amphetamine. Rats in different groups received five exposure injections of vehicle or one of five doses of Δ(9)-THC (0.4, 0.75, 1.5, 3.0, and 6.0 mg/kg i.p.) and were tested 2 days and 2 weeks later. Exposure to all but the lowest and highest doses of Δ(9)-THC enhanced the locomotor response to amphetamine (0.75 mg/kg i.p.), but all failed to enhance NAcc DA overflow in response to the drug. Moreover, exposure to 3.0 mg/kg i.p. Δ(9)-THC increased forskolin-evoked adenylyl cyclase activity in the NAcc and rats' locomotor response to the direct DA receptor agonist apomorphine (1.0 mg/kg s.c.), suggesting that Δ(9)-THC sensitized locomotor responding to amphetamine by up-regulating postsynaptic DA receptor signaling in the NAcc. Finally, amphetamine self-administration (200 μg/kg/infusion i.v.) was enhanced in amphetamine (5 × 1.5 mg/kg i.p.)-exposed rats, but not in rats exposed to Δ(9)-THC (5 × 3.0 mg/kg i.p.). Previous exposure to this dose of Δ(9)-THC modestly increased apomorphine SA (0.5 mg/kg/infusion i.v.). Thus, unlike amphetamine exposure, exposure to Δ(9)-THC does not enhance the subsequent NAcc DA response to amphetamine or promote amphetamine self-administration. Although Δ(9)-THC leads to alterations in postsynaptic DA receptor signaling in the NAcc and these can affect the generation of locomotion, these neuroadaptations do not seem to be linked to the expression of enhanced amphetamine self-administration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389094      PMCID: PMC3101004          DOI: 10.1124/jpet.111.180208

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.

Authors:  Ana Belén Martín; Emilio Fernandez-Espejo; Belén Ferrer; Miguel Angel Gorriti; Ainhoa Bilbao; Miguel Navarro; Fernando Rodriguez de Fonseca; Rosario Moratalla
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

Review 2.  Involvement of the endocannabinoid system in drug addiction.

Authors:  Rafael Maldonado; Olga Valverde; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2006-02-17       Impact factor: 13.837

3.  Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats.

Authors:  Leigh V Panlilio; Marcello Solinas; Stephanie A Matthews; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2006-05-31       Impact factor: 7.853

4.  Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats.

Authors:  Maria Ellgren; Sabrina M Spano; Yasmin L Hurd
Journal:  Neuropsychopharmacology       Date:  2006-07-05       Impact factor: 7.853

5.  Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens.

Authors:  Virgina M Pickel; Jane Chan; Christopher S Kearn; Kenneth Mackie
Journal:  J Comp Neurol       Date:  2006-03-20       Impact factor: 3.215

Review 6.  Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs.

Authors:  Paul Vezina
Journal:  Neurosci Biobehav Rev       Date:  2004-01       Impact factor: 8.989

7.  Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission.

Authors:  Cristina Cadoni; Valentina Valentini; Gaetano Di Chiara
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

8.  Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids.

Authors:  M Diana; M Melis; G L Gessa
Journal:  Eur J Neurosci       Date:  1998-09       Impact factor: 3.386

Review 9.  Exposure to nicotine and sensitization of nicotine-induced behaviors.

Authors:  P Vezina; D S McGehee; W N Green
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-09-01       Impact factor: 5.067

10.  Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine.

Authors:  Stephen A Varvel; Billy R Martin; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2007-05-12       Impact factor: 4.530

View more
  7 in total

Review 1.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

Review 2.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

3.  Previous exposure to nicotine enhances the incentive motivational effects of amphetamine via nicotine-associated contextual stimuli.

Authors:  James J Cortright; Georgia R Sampedro; Nichole M Neugebauer; Paul Vezina
Journal:  Neuropsychopharmacology       Date:  2012-05-23       Impact factor: 7.853

4.  Exposure to nicotine enhances its subsequent self-administration: contribution of nicotine-associated contextual stimuli.

Authors:  Nichole M Neugebauer; James J Cortright; Georgia R Sampedro; Paul Vezina
Journal:  Behav Brain Res       Date:  2013-12-01       Impact factor: 3.332

5.  Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice.

Authors:  Toyoshi Umezu
Journal:  ISRN Pharmacol       Date:  2012-03-20

Review 6.  One Is Not Enough: Understanding and Modeling Polysubstance Use.

Authors:  Elizabeth A Crummy; Timothy J O'Neal; Britahny M Baskin; Susan M Ferguson
Journal:  Front Neurosci       Date:  2020-06-16       Impact factor: 4.677

Review 7.  Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies.

Authors:  Dimitri Daldegan-Bueno; Lucas O Maia; Michelle Glass; Didier Jutras-Aswad; Benedikt Fischer
Journal:  Psychopharmacology (Berl)       Date:  2021-10-06       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.